Methods
Thirty-six patients with advanced breast cancer enrolled between 1988 and 1991 had serial CA-125 measurements during therapy for their disease. All the patients had received some form of prior treatment. Response to therapy was assessed by clinical palpation, chest X-ray (CXR), ultrasound (U/S) of the liver, CT scanning where CXR and U/S provided inadequate information, liver function tests (LFT), bone scanning and limited skeletal surveys. The clinical course was scored as responsive disease (RD), stable disease (SD) or progressive disease according to the UICC/WHO criteria for clinical evaluation (Miller et al., 1981) .
Responsive disease included both partial and complete responses. The patients were reviewed clinically at each attendance for chemotherapy or otherwise monthly with a full blood count, LFT and CA-125. The minimum follow-up period was 4 months with a mean of 14 months. Non clinical assessable disease was evaluated every 2-3 months.
Serum was stored at between -20 and -80'C prior to assay. The CA-125 was quantified using an immunoradiometric assay (Abbott CA-125 kit). A cut off level of > 35 iu ml-' was identified as an abnormal result (Bast et al., 1983 Figure 1 . This was one of the reasons why CA-125 and SD were in concordance in only 20% of the ten episodes seen.
None of the patients in the study had any significant past medical histories. All had normal renal function and those with abnormal LFTs had known liver metastases (nine of 12 patients). In the latter cases the CA-125 did not rise despite deteriorating LFTs. 
Discussion
Tumour markers must fulfill certain criteria if they are to be useful in clinical practice (Beastall et al., 1991) . In metastatic cancer these include sufficient sensitivity and specificity to allow early changes in management which may affect outcome. In addition tumour markers may also be seen to be saving money if they avoid unnecessary investigations (Rustin et al., 1992) . Previous studies have shown that the CA-125 may be elevated in 12-18% of patients with advanced breast cancer (Bast et al., 1983; Kawahara et al., 1986) . This suggested that CA-125 would not be a useful marker of disease activity. However, Perey et al. looked at 40 metastatic breast patients, performing three of more CA-125 assays over a period of time and found that 16 (40%) had elevated CA-125 levels at presentation. Seventeen patients (43%) had CA-125 levels that correlated with disease activity (PD+ RD + SD). They suggest that CA-125 may be a useful marker in advanced breast cancer. We agree that CA-125 is more commonly elevated in metastatic breast cancer (64%) than previously recognised. Although the sensitivity of serial CA-125 assays was only 60% for RD and 55% for PD, it preceeded clinical findings in fewer than 42% of cases. Furthermore, in 32% of progressive disease episodes, the CA-125 fell or did not rise despite being elevated (in ovarian cancer CA-125 wrongly predicts PD in fewer than 10% of cases (Rustin et al., 1992) ). Similarly in 29% of responsive disease episodes the CA-125 actually rose or remained elevated. There is no way of predicting which patients will have CA-125 values that are in concordance with their disease activity and the patients who do have CA-125 measurements which agree with disease change on one occasion may not agree on the next occassion. Only three of the 13 patients who had more than one change in disease status with a concording CA-125, continued to have a CA-125 which was in concordance with their disease.
These facts clearly show that CA-125 is not a useful marker of disease activity in metastatic breast cancer and its continued use in such patients can only be seen as wasting resources. We conclude that this data does not support the view expressed by Perey et al. that CA-125 maybe a useful marker in advanced breast cancer.
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